
|Articles|February 1, 2005
Advances provide sustained drug release for retinal disease
Baltimore—Innovative pharmaceutical delivery systems are showing promise for their potential to provide safe and effective "site-directed" therapy for retinal diseases, said Eugene de Juan Jr., MD, in the Ronald G. Michels Memorial Lecture at the Current Concepts of Ophthalmology meeting.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AI in ophthalmology research: Ethical implications for medical students
2
How AI is reshaping ophthalmology in 2025 and beyond
3
From bench to bedside: Evolving realities of gene therapy for inherited retinal diseases
4
8 things to know about aflibercept 8 mg for retinal vascular disease
5












































